SCHEMBL171279

SCHEMBL171279

COc1cc(Cl)ccc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
CYP3A4 P08684 5/20 0.61
TSHR P16473 4/20 0.61
TDP1 Q9NUW8 3/20 0.61
HSD17B10 Q99714 1/20 0.61
GAA P10253 1/20 0.54
ALOX15 P16050 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TRPV4 Q9HBA0 1/20 0.50
HTT P42858 1/20 0.50
APP P05067 2/20 0.48
NPC1 O15118 1/20 0.48
ADRA2B P18089 1/20 0.48
PTGS1 P23219 1/20 0.48
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29811646 1.00 ALDH1A1 (0.61) ALDH1A1CYP3A4TSHRTDP1HSD17B10
Hydrochloric Acid SCHEMBL365098 0.98 ALDH1A1 (0.61) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL29288585 0.84 ALDH1A1 (0.77) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL92069 0.82 ALDH1A1 (0.59) ALDH1A1CYP3A4TSHRTDP1GAA
SCHEMBL29565516 0.82 ALDH1A1 (0.59) ALDH1A1CYP3A4TSHRTDP1GAA
SCHEMBL11218464 0.81 ALDH1A1 (0.61) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL1298828 0.81 ALDH1A1 (0.56) ALDH1A1CYP3A4TSHRTDP1HSD17B10
Hydrochloric Acid SCHEMBL365099 0.80 ALDH1A1 (0.61) ALDH1A1CYP3A4TSHRTDP1GAA
SCHEMBL11791506 0.79 ALDH1A1 (0.48) ALDH1A1CYP3A4TSHRTDP1HSD17B10
SCHEMBL11791512 0.79 ALDH1A1 (0.48) ALDH1A1CYP3A4TSHRTDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3405453-B1 A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) 2024-05-29 EP claimed
CN-108884032-B Method for preparing poly (carbonate-etherimide) compounds PTT全球化学股份有限公司 2021-10-15 CN claimed
US-10759904-B2 Method for preparing poly(carbonate-etherimide) compound PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) 2020-09-01 US claimed
US-20190202980-A1 METHOD FOR PREPARING POLY(CARBONATE-ETHERIMIDE) COMPOUND PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) 2019-07-04 US claimed
EP-3405453-A2 A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND PTT Global Chemical Public Company Limited (TH) 2018-11-28 EP claimed
CN-104744311-A Synthesis method of bifenazate MAISON CHEMICAL CO LTD 2015-07-01 CN claimed
EP-2321316-B1 SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES MITSUBISHI TANABE PHARMA CORP (JP) 2014-03-12 EP claimed
CN-102993023-A Preparation method of mono-substituted para-chloroaniline UNIV SHANGHAI ENG SCIENCE 2013-03-27 CN claimed
EP-1506196-B1 PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2012-01-18 EP claimed
US-4288362-A Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component BAYER AKTIENGESELLSCHAFT (DE) 1981-09-08 US claimed
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-04-09 US disclosed
EP-4644387-A2 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2025-11-05 EP disclosed
US-12428406-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 US disclosed
WO-2025100475-A1 COMPOSITION FOR IMAGE RECORDING AND METHOD FOR PRODUCING SAME キヤノン株式会社 2025-05-15 WO disclosed
US-3982019-A Insecticidal compositions containing trifluoromethyl ureas and method of controlling insects using said compositions VELSICOL CHEMICAL CORPORATION (US) 1976-09-21 US disclosed
US-3971738-A Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component CIBA-GEIGY AG (CH) 1976-07-27 US disclosed
US-3947247-A STABILIZER COMPOSITION FOR DYESTUFFS CENTRAL MICHIGAN UNIVERSITY BOARD OF TRUSTEES (US) 1976-03-30 US disclosed
US-3947434-A 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines MORTON-NORWICH PRODUCTS, INC. (US) 1976-03-30 US disclosed
US-3933785-A Azo compounds CIBA-GEIGY AG (CH) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 ALDH1A1 1142/4885CYP3A4 684/4885TSHR 1114/4885
US-12428406-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS ALDH1A1 1538/4885CYP3A4 4374/4885TSHR 3846/4885
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, MDM2 ALDH1A1 4027/4885CYP3A4 2723/4885TSHR 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.